Revolutionizing Healthcare by Tracking and Understanding Human Cells during Disease

Leistungen

This map will i) capture all courses currently offered and/or planned to be offered in the scientific topics of LifeTime, ii) identify the institutions that can provide/are providing the gold standards and best experts in teaching specialised methods, techniques, approaches, research strategies etc., iii) record the geographic coverage across the 28 EU countries

Disease selection criteria and process

The criteria and metrics will define how to select diseases that should be the immediate focus for the application of the LifeTime technology platform.

Stakeholder/target group map

The stakeholder/target group map will include groups such as the general public (customised to age groups and gender), patients, medical practitioners, the scientific community, the media, industry and business, policymakers, third sector organisations, funding organisations, member states and associate countries.

“Business plan”

A task force will propose a financial plan including cost division for the core project (personnel, equipment, consumables) and budget allocation for open calls.

Revised communication strategy

The communication strategy will involve using a diversity of media channels: project website, project video, social media, E-newsletter, press releases, information material (slides, brochures), interviews, outreach events. It will be revised in M8 to ensure optimal dissemination of the LifeTime results and vision.

Strategies to address ELSI white paper

The white paper that will contain guidelines for tissue and data stewardship, i.e. on how LifeTime human data and tissues will be obtained, consented, and used by researchers and/or clinicians. The white paper will also contain guidelines on how technology risks should be handled, mitigated and communicated to the society.

LifeTime Strategic Research Agenda

Integration of all elements into a coherent Roadmap.

Flagship Launchpad mechanism

A flexible Launchpad mechanism will be established to run for the duration of the Flagship. It will ensure timely, smooth and efficiently phased introduction of diseases to be studied by LifeTime, as well as to identify new opportunities to study diseases during the operational phase of the Flagship.

4D longitudinal analysis white paper

In task 3.4, the 4D-working group will deliver a white paper based on disruptive meetings involving expert pathologists and genomics/microscopy experts as well as a call for research synopses.

ELSI governance concept draft

The concept for ethics management within the Flagship governance will propose a model to monitor, identify and address ethical and societal issues as they arise in the Flagship projects and how the consortium has been responding to these and what new challenges are expected to emerge.

Disease Area Model Maps

At the LifeTime opening conference, WP5 will engage the scientific community and invited experts in mapping sessions, to produce Disease Area Model Maps (DAMM). Each DAMM will outline the criteria and metrics for identifying the most appropriate/relevant existing disease models as well as those currently under development.

LifeTime innovation framework

The LifeTime innovation framework will describe innovative ways of interacting and sharing risk between stakeholders, supporting public/private partnerships, and business creation.

Industry role in LifeTime governance

The level of involvement of the private sector within LifeTime governance will be described with respect to the industry strategy and innovation framework.

In vivo models white paper

The white paper will outline clear technology development objectives and how they could be implemented in the S&T Roadmap.

Technology mapping report

At the LifeTime opening conference leading international experts and the wider scientific community will discuss the state-of-the-art, challenges and progress in potential technologies to be integrated in the LifeTime Technology Platform. This will be summarised in a report.

State-of-the-art report

"At the opening LifeTime conference, WP4 will engage with the community, to assess the state-of-the-art for data science, artificial intelligence and machine learning and identify current challenges to realising LifeTime objectives. This will be summarised in a report supplemented by information gathered at the ""unconference"" in Barcelona and input from various working groups in WP 4."

Public consultation report

The public consultation process (focus group, online survey or telephone interviews) will be performed with a subcontractor to provide further insights, and support the development of citizen and patient engagement projects.

Integration white paper

In task 4.3 the “integration” working group will deliver a white paper defining challenges and strategies for data benchmarking, integration and visualisation as well as guidelines for performance analysis for benchmarking by developers of computational methodologies.

Disease(s) selection report

The report will list all diseases evaluated, working groups established for each disease area, the scientific and medical opportunities that can be leveraged using the LifeTime platform for each evaluated disease (as developed in a dedicated workshop) as well as preliminary recommendations for selected diseases.

Flagship ELSI report

A workshop will identify the priority areas with ethical and societal challenges, additional expertise required to address specific measures and establish task forces for each area. The results will be summarised in a meeting report.

Technoshot reports

WP5 will form an expert working group to define the steps required to develop organoid technologies to fulfil the LifeTime objectives. Several 1-day disruptive meetings will yield a portfolio of “technoshots”, concise reports outlining immediately actionable plans and timelines of high-impact technology development opportunities.

Perturbation tools report

The white paper will outline technologies for the functional perturbation of disease models for a mechanistic understanding of gene expression, metabolic and proteomic changes observed in patients over time.

Activities and financial reporting

Detailed report on all activities conducted within the CSA as well as the allocation and use of funds awarded to the project.

Data white paper

In task 4.4 the “data” working group will deliver a white paper defining current and upcoming challenges for large-scale data sharing and management.

CSA data management plan

This plan will follow the guidelines on data management of H2020, take into account the regulations such as the GDPR and be revised over the course of the preparatory action.

Flagship communication/dissemination strategy

The strategy will cover various media channels: social media, web, video, podcasts, offline media/press, newsletters, collaborative software technologies etc.. Tools aiding internal communication will be investigated with the goal of establishing an internal communication platform.

Single-cell omics white paper

In task 3.2 the 1D-working group will define criteria and metrics for selection of the multi-omics technologies of the LifeTime technology platform. The white paper will identify single-cell multi-omics technologies to be developed and implemented in the S&T Roadmap.

LifeTime industry strategy report

This strategic plan will define important platforms for engagement (e.g. formal consortia, regular sharing of research findings, scientific partnerships, co-location of research, networking, and tracking of technologies along the pipeline) with different industry sectors, geographic areas, enterprise sizes, and types of interaction (e.g. operative, enabling, funding, consulting, societal engagement).

Blueprint of LifeTime Academy

The Blueprint of the LifeTime Academy will be a concept of an integrated training programme, consisting of workshops, practical courses, lecture series, internships etc.

Adaptive white paper

In task 4.2, the “adaptive” working group will deliver a white paper defining current and upcoming challenges for adaptive experimental design.

Flagship website specification plan

The specifications for the website will be outlined based on the stakeholder and target group analysis.

Funding sources/education resources

The education resources report will summuarise appropriate funding mechanisms.

3D imaging white paper

In task 3.3 the 3D-working group will define current and upcoming technologies for integrating high-content and/or super-resolution microscopy in LifeTime, as well as metrics for scalable 3D methods in clinical samples or disease models. The white paper will identify the imaging technologies to be part of the LifeTime technology platform and specify how they will be developed within the S&T Roadmap in WPX.

Health white paper

In task 4.5 the “Health” group will work with WP3 (task 3.5) and identify long term objectives of LifeTime requiring genetic information and health record mining. This will be summarized in a white paper.

Governance/structure models white paper

Activities under task 2.1 will yield a white paper on governance and structure models.

Flagship governance structure report

Based on the Governance/structure white paper (D2.1), potential governance models for the Flagship will be proposed to implement the organisational structure (D2.2) and the business plan (D2.3).

Flagship Data Management Plan

Activities in WP4 will describe the types of data to be generated in LifeTime. A data management plan will be devised based on the information collated in tasks 4.1 to 4.6.

Market and impact study

The outsourced market and impact study of the LifeTime technologies will be based on D7.1, the Industry ecosystem mapping.

Veröffentlichungen

LifeTime and improving European healthcare through cell-based interceptive medicine

Autoren: Nikolaus Rajewsky, Geneviève Almouzni, Stanislaw A. Gorski, Stein Aerts, Ido Amit, Michela G. Bertero, Christoph Bock, Annelien L. Bredenoord, Giacomo Cavalli, Susanna Chiocca, Hans Clevers, Bart De Strooper, Angelika Eggert, Jan Ellenberg, Xosé M. Fernández, Marek Figlerowicz, Susan M. Gasser, Norbert Hubner, Jørgen Kjems, Jürgen A. Knoblich, Grietje Krabbe, Peter Lichter, Sten Linnarsson, J
Veröffentlicht in: Nature, 2020, ISSN 0028-0836
Herausgeber: Nature Publishing Group
DOI: 10.1038/s41586-020-2715-9

Thinking “ethical” when designing an international, cross‐disciplinary biomedical research consortium

Autoren: Maria‐Elena Torres‐Padilla Annelien L Bredenoord Karin R Jongsma Astrid Lunkes Luca Marelli Ines Pinheiro Giuseppe Testa
Veröffentlicht in: The EMBO journal, 2020, ISSN 0261-4189
Herausgeber: Nature Publishing Group

Leistungen

Veröffentlichungen

Diese Seite teilen

Herunterladen